|Disease Group:||Leukemia; Lymphoma; Myeloma|
|Phase of Study:||Phase II|
|Treatment Location:||Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions|
|Estimated Length of Stay in Houston:||Patients are expected to be hospitalized for 5-6 weeks for the transplant. |
After discharge there is no planned admission unles clinically indicated.
|Supported By:||Otsuka Pharmecuticals|
|Return Visit:||This protocol calls for weekly assesment after discharge during the first 100 |
days post-transplant. Patients are to return 6 and 12 months after transplant.
However, return visits may occur more frequently as clinically indicated.
|Home Care:||There is no home care as part of this study.|